Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: a randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects

作者：Patino Rodriguez Omar; Maria Martinez Medina Rosa; Torres Roque Irma; Martinez Delgado Maricela; Susana Mares Garcia America; Escobedo Moratilla Abraham; Covarrubias Pinedo Amador; Arzola Paniagua Angelica; Luis Herrera Torres Jose; Perez Urizar Jose^*

来源：Frontiers in Pharmacology, 2015, 6: 4.

DOI：10.3389/fphar.2015.00004

• atorvastatin
• fenofibrate
• pharmacokinetic interaction
• combination
• LC-MS-MS

Several clinical trials have substantiated the efficacy of the co-administration of statins like atorvastatin (ATO) and fibrates. Without information currently available about the interaction between the two drugs, a pharmacokinetic study was conducted to investigate the effect when both drugs were co-administered. The purpose of this study was to investigate the pharmacokinetic profile of tablets containing ATO 20 mg, or the combination of ATO 20 mg with fenofibrate (FNO) 160 mg administered to healthy Mexican volunteers. This was a randomized, two-period, two-sequence, crossover study; 36 eligible subjects aged between 2050 years were included. Blood samples were collected up to 96 h after dosing, and pharmacokinetic parameters were obtained by non-compartmental analysis. Adverse events were evaluated based on subject interviews and physical examinations. Area under the concentration-time curve (AUC) and maximum plasma drug concentration (C-max) were measured for ATO as the reference and ATO and FNO as the test product for bioequivalence design. The estimation computed (90% confidence intervals) for ATO and FNO combination versus ATO for C-max, AUC(0-t) and AUC(0-infinity), were 102,09, 125,95, and 120,97%, respectively. These results suggest that ATO and FNO have no relevant clinical-pharmacokinetic drug interaction.

• 出版日期2015-1-29